Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis—Case Report and Literature Review

Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis—Case Report and Literature Review

Idiopathic pulmonary fibrosis is a poorly prognosed form of progressive interstitial pneumonia. Patients with IPF have a significantly increased risk of developing lung cancer, which further worsens the course of the disease. The most common histological types of LC among patients with IPF are squam...

Full description

Bibliographic Details
Main Authors:	Maria Grodkiewicz, Pawel Koziel, Izabela Chmielewska, Marta Adamczyk Korbel, Janusz Milanowski
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Current Oncology
Subjects:	idiopathic pulmonary fibrosis (IPF) lung cancer (LC) small cell lung cancer (SCLC) carboplatin–etoposide chemotherapy pirfenidone
Online Access:	https://www.mdpi.com/1718-7729/29/7/401

Similar Items

Chemotherapy for small cell lung cancer: a comprehensive review
by: Syed Mustafa Karim, et al.
Published: (2012-04-01)

Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
by: Céline Audibert, et al.
Published: (2016-08-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
by: KM Roach, et al.
Published: (2021-10-01)

Comparison of oral versus intravenous etoposide in the management of small‐cell lung cancer; A real‐world, population‐based study
by: Hatim Karachiwala, et al.
Published: (2021-01-01)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
by: Mark H. Gotfried, et al.
Published: (2018-06-01)

Efficacy and Safety of Anti–Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial
by: Shun Lu, PhD, MD, et al.
Published: (2023-04-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Acute Exacerbation of Idiopathic Pulmonary Fibrosis
by: Tomoo Kishaba
Published: (2019-03-01)

Comparative study between pirfenidone and traditional drugs in treatment of idiopathic pulmonary fibrosis
by: Ramadan M Nafee, et al.
Published: (2019-01-01)

Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study
by: Myung Jin Song, et al.
Published: (2021-05-01)

Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions
by: Won-Il Choi
Published: (2021-03-01)

Clinical characteristics of patients with familial idiopathic pulmonary fibrosis (f-IPF)
by: Ekaterina Krauss, et al.
Published: (2019-07-01)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
by: James Patrick Finnerty, et al.
Published: (2021-12-01)

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status
by: Nobuaki Mamesaya, et al.
Published: (2023-03-01)

Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function
by: Xiyue Zhang, et al.
Published: (2021-04-01)

The impact of respiratory reactance in oscillometry on survival in patients with idiopathic pulmonary fibrosis
by: Tatsuru Ishikawa, et al.
Published: (2024-01-01)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01)

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
by: Shih-Lung Cheng, et al.
Published: (2022-09-01)

Potential targeted therapy based on deep insight into the relationship between the pulmonary microbiota and immune regulation in lung fibrosis
by: Tao Zhang, et al.
Published: (2023-01-01)

A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen
by: Liu F, et al.
Published: (2020-10-01)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)

Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio
by: S. N. Avdeev, et al.
Published: (2018-10-01)

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
by: Moua T, et al.
Published: (2019-01-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
by: Goran Nadir Salih, et al.
Published: (2016-09-01)

The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
by: Andreas Guenther, et al.
Published: (2018-07-01)

Mapping brain endophenotypes associated with idiopathic pulmonary fibrosis genetic riskResearch in context
by: Ali-Reza Mohammadi-Nejad, et al.
Published: (2022-12-01)

Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
by: Ho Young Lee, et al.
Published: (2023-10-01)

Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study
by: Jang Ho Lee, et al.
Published: (2023-02-01)

Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
by: V. Cottin
Published: (2012-06-01)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2017-11-01)

Long-Term Survival and Stable Disease in a Patient with Extensive-Stage Small-Cell Lung Cancer after Treatment with Carboplatin, Etoposide and Atezolizumab
by: Reyes Bernabé, et al.
Published: (2024-01-01)

Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature
by: Mihoko Imaji, et al.
Published: (2021-05-01)

Complications in Idiopathic Pulmonary Fibrosis: Focus on Their Clinical and Radiological Features
by: Federica Galioto, et al.
Published: (2020-07-01)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2018-01-01)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
by: John N. Shumar, et al.
Published: (2021-05-01)

NERVES, COUGH, AND IDIOPATHIC PULMONARY FIBROSIS
by: Nicholas Kim Harrison, et al.
Published: (2015-05-01)

Idiopathic pulmonary fibrosis - problematic rare lung disease. Pathogenesis, diagnosis, treatment and prognosis
by: Aleksander Kłos, et al.
Published: (2022-11-01)

Combination of Niclosamide and Pirfenidone Alleviates Pulmonary Fibrosis by Inhibiting Oxidative Stress and MAPK/Nf-κB and STATs Regulated Genes
by: Hanaa Wanas, et al.
Published: (2023-05-01)